Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (181-190 of 250) with videos related to

Pageof 25
Sort By:
Blood|June 15, 2006
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyMaría-Victoria Mateos, José-M Hernández, Miguel-T Hernández, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
The American Journal of Pathology|September 15, 2012
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trialsBruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, et al.
Blood|August 15, 2012
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialMaría-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood|January 13, 2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistanceBruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
Blood Cancer Journal|April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma GroupAdrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Leukemia|March 9, 2018
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability rolePaula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Blood|September 6, 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Albert Oriol, Rafael Rios, et al.
Pageof 25

Showing results (181-190 of 250) with videos related to

Sort By:
Pageof 25
Blood|June 15, 2006
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyMaría-Victoria Mateos, José-M Hernández, Miguel-T Hernández, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
The American Journal of Pathology|September 15, 2012
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trialsBruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, et al.
Blood|August 15, 2012
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialMaría-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Blood|January 13, 2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistanceBruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
Blood Cancer Journal|April 26, 2022
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma GroupAdrian Mosquera Orgueira, Marta Sonia González Pérez, Jose Diaz Arias, et al.
Leukemia|March 9, 2018
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability rolePaula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Blood|September 6, 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Albert Oriol, Rafael Rios, et al.
Pageof 25